Skip to ContentSkip to Navigation
founded in 1614  -  top 100 university
University Medical Center Groningen

Staff

Klaas Kok, PhD

MSc: Chemistry, specialization in Biochemistry
PhD thesis: Characterization of 3p deletions in lung cancer, 1994

Papers in GoogleScholar

Email: k.kok@umcg.nl
Phone: +31 (0)50 361 7100

Keywords: RCC, SCLC, tumour-suppressor genes, miRNA, array-CGH

News

Dec. 2015: KWF grant awarded for project entitled "Towards a unifed assay for the detection of driver mutations with treatment implications in lung cancer"

Nov. 2015: More than 1000 citations achieved for ISCA Consortium's paper "Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies" by Miller DT et al. (including Klaas Kok), Am J Human Genetics 2010;86(5):749-64. Open Access

Current work

My main research objectives are to elucidate the role of the short arm of chromosome 3 in the development of cancer. Loss of 3p occurs frequently in many types of solid tumours, most notably SCLC and RCC. Despite decades of research this puzzle has still not been solved completely. Recently, we identified SETD2 as a gene from 3p with tumour-suppressor-like characteristics in RCC. As SETD2 is known to be responsible for the trimethylation of histon3 at the K36 position, we are now investigating how changes in the chromatin structure can lead to, or contribute to, the development of RCC. more

In parallel with this work, we are focusing on the possible involvement of non-coding RNA molecules that originate from 3p.

Since I also have a strong interest in advances in technology, I am involved in the Development and Innovation section (O&I), investigating the technical aspects of applying array-based CGH in research work and in post-natal diagnostics (5GPM, 5 genes per minute).

I am supervising a PhD student, Ferronika Paranita (2013-2017). She has been awarded a NUFFIC fellowship to work on “ The development of new diagnostic tools for monitoring and treatment preferences of patients with clear cell renal cell carcinoma; genetic mutations as potential novel molecular markers”. She comes from the Department of Molecular Pathology, Gadjah Mada University, Yogyakarta, Indonesia .

Recent papers

Laatst gewijzigd:08 augustus 2016 13:12